


7th

INTERNATIONAL CONFERENCE ON

THROMBOSIS AND HEMOSTASIS ISSUES IN CANCER

PROGRAM



MAY 9-11, 2014

Seminario Vescovile
"Giovanni XXIII"

Bergamo, Italy



www.ichic.com



AUSPICES

The meeting is held under the auspices of



Società
Italiana
di Ematologia



CONFERENCE ORGANIZATION



CONFERENCE CHAIRMEN

Anna Falanga

Department of Immunohematology
and Transfusion Medicine
& Hemostasis and Thrombosis Center
Hospital Papa Giovanni XXIII
Piazza OMS, 1
24127 Bergamo - Italy
E-mail: annafalanga@yahoo.com

Benjamin Brenner

Department of Hematology
and Bone Marrow Transplantation
& Thrombosis and Hemostasis Unit
Rambam Health Care Campus
Technion, Israel Institute of Technology
POB 9602 Haifa, Israel
E-mail: b_brenner@rambam.health.gov.il

Frederick R. Rickles

The George Washington University
Karzen Cancer Center
2150 Pennsylvania Ave NW
Washington, DC 20037, USA
& Division of Hematology
Department of Medicine
Veterans Affairs Medical Center
50 Irving St NW
Washington, DC 20422, USA
E-mail: frederick.rickles@gmail.com

ORGANIZING COMMITTEE

Anna FALANGA

Bergamo, Italy

Frederick R. RICKLES

Washington, DC, USA

Benjamin BRENNER

Haifa, Israel

Roberto LABIANCA

Bergamo, Italy

Marina MARCHETTI

Bergamo, Italy

Alfonso VIGNOLI

Bergamo, Italy

Galit SARIG

Haifa, Israel

Laura RUSSO

Bergamo, Italy

Carmen Julia TARTARI

Bergamo, Italy

SCIENTIFIC SECRETARIAT

Anna Falanga • Marina Marchetti • Alfonso Vignoli

Department of Immunohematology and Transfusion Medicine
Hospital Papa Giovanni XXIII
Piazza OMS, 1 - 24127 Bergamo - Italy
scientificsecretariat@icthc.com

ORGANIZING SECRETARIAT

Servizi C.E.C. Srl

Via G. Verdi, 18 • 24121 Bergamo • Italy
Phone +39.035.249899 • Fax +39.035.237852 • info@icthc.com



SPONSORS

Gold



Bayer HealthCare



Silver



Bronze

BRISTOL
MYERS



FACULTY



Giancarlo AGNELLI , Italy
Cihan AY , Austria
Alessandra BALDUINI , Italy
Tiziano BARBUI , Italy
Mattias BELTING , Sweden
Benjamin BRENNER , Israel
Marina CAMERA , Italy
Elisabetta CASTOLDI , Italy
Marco CATTANEO , Italy
Armando D'ANGELO , Italy
Erica DE CANDIA , Italy
Luigi DE MARCO , Italy
Valerio DE STEFANO , Italy
Elisabetta DEJANA , Italy
Marcello DI NISIO , Italy
Françoise DIGNAT-GEORGE , France
Wassim EL NEMER , France
Anna FALANGA , Italy
Dominique FARGE-BANCEL , France
Augusto B. FEDERICI , Italy
Charles W. FRANCIS , USA
Raffaella GIAVAZZI , Italy
Johan W.M. HEEMSKERK , The Netherlands
Menno V. HUISMAN , The Netherlands
Licia IACOVIELLO , Italy
Ayaj K. KAKKAR , UK
Peter W. KAMPHUISEN , The Netherlands
Nigel S. KEY , USA
Alok A. KHORANA , USA
Paul A. KYRLE , Austria
Roberto LABIANCA , Italy

Agnes Y.Y. LEE , Canada
Marcel M. LEVI , The Netherlands
Mark N. LEVINE , Canada
Howard LIEBMAN , USA
Francesco LO COCO , Italy
Gary H. LYMAN , USA
Mario MANDALÀ , Italy
Manuel MONREAL , Spain
Yona NADIR , Israel
Simon NOBLE , UK
Carlo PATRONO , Italy
Paolo PRANDONI , Italy
Domenico PRISCO , Italy
Janusz RAK , Canada
Pieter H. REITSMA , The Netherlands
Frederick R. RICKLES , USA
Wolfram RUF , USA
Per Morten SANDSET , Norway
Sam SCHULMAN , Canada
Paolo SIMIONI , Italy
Sergio SIRAGUSA , Italy
David STEGNER , Germany
Giulia TARABOLETTI , Italy
Hugo ten CATE , The Netherlands
Angelo VACCA , Italy
Claudio VELATI , Italy
Henry H. VERSTEEG , The Netherlands
Ilene C. WEITZ , USA
Richard H. WHITE , USA
Jeffrey I. ZWICKER , USA



PROGRAM OVERVIEW

Friday May 9th, 2014

10.00

Secretariat Opening

14.00 Congress Opening

14.15 **Plenary Session 1**
Epidemiology and risk factors for thrombosis in cancer
Auditorium

16.30 Coffee Break

17.00 **Plenary Session 2**
Hypercoagulability in cancer / Biomarkers for VTE
Auditorium

19.15

19.30 **3rd Simon Karpatkin Memorial Lecture**
Auditorium

20.30 Welcome Reception

Saturday May 10th, 2014

8.00 Secretariat Opening

8.15 **Plenary Session 3**
Bleeding complications, microangiopathies and thrombocytopenias
Auditorium

10.30 Coffee Break

11.00 **Plenary Session 4**
Hemostatic system and cancer progression
Auditorium

13.15 Lunch

14.15 **Plenary Session 5**
Thrombosis in hematological disorders
Auditorium

16.30 Coffee Break

17.00 **Plenary Session 6**
Thromboprophylaxis in cancer
Auditorium

19.15

20.30 Presidential Dinner
(by invitation only)

Sunday May 11th, 2014

8.00 Secretariat Opening

8.15 **Plenary Session 7**
Platelets and vascular endothelium
Auditorium

10.30 Coffee Break

11.00 **Plenary Session 8**
Treatment of thrombosis in cancer
Auditorium

13.15 Lunch

14.30 **Poster Discussion Sessions**
Session 1 Room A
Session 2 Room B
Session 3 Room C

15.45 Coffee Break

16.15 **Poster Discussion Sessions**
Session 4 Room A
Session 5 Room B
Session 6 Room C

17.30 Meeting Closed



Friday May 9th, 2014

CONGRESS OPENING

- 14.00 – 14.15** Opening remarks from the Conference Chairmen
A. Falanga, F.R. Rickles, B. Brenner and representatives of Institutional Authorities

SCIENTIFIC SESSIONS (Auditorium)

14.15 – 16.30 PLENARY SESSION 1: EPIDEMIOLOGY AND RISK FACTORS FOR THROMBOSIS IN CANCER

Chairs: F.R. Rickles (USA), B. Brenner (Israel)

- 14.15 – 14.40** Advances in the diagnosis and management of pulmonary embolism **PL-01**
M.V. Huisman (The Netherlands)

- 14.40 – 15.05** Predicting recurrent thrombosis in cancer: is it possible? **PL-02**
P.A. Kyrle (Austria)

- 15.05 – 15.30** Lymphoma and VTE: influence on mortality **PL-03**
R.H. White (USA)

- 15.30 – 15.55** New findings from the RIETE study **PL-04**
M. Monreal (Spain)

SELECTED ABSTRACTS

- 15.55 – 16.10** Non-O blood group, age at cancer diagnosis and asparaginase therapy are independent risk factors for venous thrombotic events in children with cancer **OC-01**
M. Spavor, J. Halton, K. Dietrich, E. Shereck, S.J. Israels, S. Abish, T. Rodostits, J. Yong, Y. Yasui, L.G. Mitchell (Canada)

- 16.10 – 16.25** Role of arterial cardiovascular risk factors in the pathogenesis of cancer-related VTE **OC-02**
F. Dentali, M. Mantiero, J. Muzzolon, A. Pastore, W. Ageno, G. Pinotti (Italy)

- 16.30 – 17.00** Coffee Break

17.00 - 19.15 PLENARY SESSION 2: HYPERCOAGULABILITY IN CANCER / BIOMARKERS FOR VTE

Chairs: N.S. Key (USA), A. D'Angelo (Italy)

- 17.00 – 17.25** Update on thrombotic risk stratification strategies **PL-05**
A.A. Khorana (USA)



PROGRAM

- 17.25 – 17.50 Thrombogenic and fibrinolytic properties of microparticles** **PL-06**
F. Dignat-George (France)
- 17.50 – 18.15 Risk factors for VTE in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS)** **PL-07**
C. Ay (Austria)
- 18.15 – 18.40 Unconventional antithrombotics in cancer associated thrombosis** **PL-08**
J.I. Zwicker (USA)
- SELECTED ABSTRACTS**
- 18.40 – 18.55 Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: further evidence of a prothrombotic role** **OC-03**
C.M. Radu, M.T. Sartori, E. Campello, P. Ciccarino, A. Della Puppa, L. Spiezia, R. Scienza, P. Simioni (Italy)
- 18.55 – 19.10 Plasma markers of hemostatic activation, fibrinolysis, and angiogenesis in prostate cancer and advanced solid tumors: relationship to stage and prognosis** **OC-04**
G. Kaur, A. Ireland, P. Christos, M. Mikhail, J. Chapin, D. Nanus, S. Tagawa (USA)
- 19.30 – 20.30 THIRD SIMON KARPATKIN MEMORIAL LECTURE**
Chair: A. Falanga (Italy)
Introduction: F.R. Rickles (USA)
- Oncogenes and coagulation system - forces that modulate dormant and aggressive states in cancer**
J. Rak (Canada)

Saturday May 10th, 2014

- 08.15 - 10.30 PLENARY SESSION 3:
BLEEDING COMPLICATIONS, MICROANGIOPATHIES AND THROMBOCYTOPENIAS**
Chairs: P.M. Sandset (Norway), C. Velati (Italy)
- 08.15 – 08.40 Bleeding complications during anticoagulation in cancer** **PL-09**
P.W. Kamphuisen (The Netherlands)
- 08.40 – 09.05 Supportive management with blood products for cancer patients** **PL-10**
A.B. Federici (Italy)
- 09.05 – 09.30 Thrombocytopenia in cancer** **PL-11**
H. Liebman (USA)

PROGRAM



- 09.30 – 09.55 Cancer-related coagulopathies** **PL-12**
M.M. Levi (The Netherlands)
- SELECTED ABSTRACTS**
- 09.55 – 10.10 Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia** **OC-05**
J. Thaler, I. Pabinger, C. Ay (Austria)
- 10.10 – 10.25 Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism receiving anticoagulation** **OC-06**
B. Zalunardo, D. Farge-Bancel, J. Trujillo-Santos, P. Deboureau, A. Bura-Riviere, E.M. Rodriguez-Beltrán, P. Di Micco, A. Visonà, D. Zeltser, M. Monreal and the RIETE Investigators. (Spain, Italy, France, Israel)
- 10.30 – 11.00 Coffee Break**
- 11.00 - 13.15 PLENARY SESSION 4:
HEMOSTATIC SYSTEM AND CANCER PROGRESSION**
Chairs: H. ten Cate (The Netherlands), R. Giavazzi (Italy)
- 11.00 – 11.25 Tumor-expressed coagulation proteases** **PL-13**
H.H. Versteeg (The Netherlands)
- 11.25 – 11.50 Role of the protein C receptor in cancer progression** **PL-14**
W. Ruf (USA)
- 11.50 – 12.15 Heparanase multiple effects in cancer** **PL-15**
Y. Nadir (Israel)
- 12.15 – 12.40 Glycosaminoglycans as anti-cancer targets** **PL-16**
M. Belting (Sweden)
- SELECTED ABSTRACTS**
- 12.40 – 12.55 Multicentric hypercoagulation screening to predict risk assessment, early diagnosis and prognosis in cancer patients: the HYPERCAN study** **OC-07**
M. Marchetti, G. Masci, A. Santoro, F. De Braud, L. Celio, R. Labianca, M. Mandalà, B. Merelli, C. Tondini, G. Gasparini, R. Sarmiento, C. Tartari, C. Giaccherini, F. Piras, C. Verzeroli, L. Barcella, A. Vignoli, and A. Falanga on behalf of the HYPERCAN Investigators. (Italy)
- 12.55 – 13.10 The tissue factor-thrombin pathway is upregulated in the stroma of pre-invasive breast cancer and further upregulated in aggressive invasive breast cancer phenotypes** **OC-08**
H. Shaker, N.J. Bundred, S. Pritchard, S. L. Nicholson, H. Albadry, G. Landberg, C.C. Kirwan (UK)
- 13.15 – 14.15 Lunch**



PROGRAM

- 14.15 - 16.30 PLENARY SESSION 5:
THROMBOSIS IN HEMATOLOGICAL DISORDERS**
Chairs: C.W. Francis (USA), T. Barbui (Italy)
- 14.15 – 14.40 Microenvironment and multiple myeloma spread PL-17**
A. Vacca (Italy)
- 14.40 – 15.05 Abnormal adhesion of red blood cells in polycythemia vera PL-18**
W. El Nemer (France)
- 15.05 – 15.30 Thrombo-hemorrhagic deaths in acute promyelocytic leukemia PL-19**
F. Lo Coco (Italy)
- 15.30 – 15.55 Role of complement in thrombosis PL-20**
I.C. Weitz (USA)
- SELECTED ABSTRACTS**
- 15.55 – 16.10 Genetic predisposition and induced pro-inflammatory/pro-oxidative
status may explain increased atherothrombotic risk during
TKI treatment in chronic myeloid leukemia patients OC-09**
L. Puccetti, L. Aprile, S. Galimberti, A. Gozzini, F. Scarpini, M. Defina, F. De Majo, C. Baratè,
A. Sicuranza, V. Candi, B. Scappini, D. Raspadori, A. Gozzetti, A. Bosi, M. Petrini and M.
Bocchia (Italy)
- 16.10 – 16.25 Spectrum of thrombin generation from normal
controls to MGUS to multiple myeloma OC-10**
B. Lipe, M. Roengvoraphoj, J. He, R. Reyes, A. Yacoub, T. Lin, D. Ornstein (USA)
- 16.30 – 17.00 Coffee Break**
- 17.00 - 19.15 PLENARY SESSION 6:
THROMBOPROPHYLAXIS IN CANCER**
Chairs: D. Farge-Bancel (France), R. Labianca (Italy)
- 17.00 – 17.25 Guidelines for thromboprophylaxis in cancer patients: future challenges PL-21**
G.H. Lyman (USA)
- 17.25 – 17.50 Experience with the direct factor Xa inhibitors in cancer PL-22**
M.N. Levine (Canada)
- 17.50 – 18.15 New strategies for VTE prevention in cancer PL-23**
G. Agnelli (Italy)

PROGRAM



- 18.15 – 18.40** Heparins and cancer survival: where do we stand? **PL-24**
S. Noble (UK)

SELECTED ABSTRACTS

- 18.40 – 18.55** A survey of thrombosis experts evaluating practices and opinions regarding venous thromboprophylaxis in patients with active cancer hospitalized with an acute medical illness **OC-11**
P. Moretto, G. Le Gal, M. Carrier (Canada)

- 18.55 – 19.10** Multi-modality assessment of pharmacological thromboprophylaxis for lung cancer patients **OC-12**
M. Alexander, S. Kirsá, M. MacManus, D. Ball, B. Solomon & K. Burbury (Australia)

Sunday May 11th, 2014

08.15 - 10.30 PLENARY SESSION 7: PLATELETS AND VASCULAR ENDOTHELIUM

Chairs: A. Falanga (Italy), M. Cattaneo (Italy)

- 08.15 – 08.40** New models of platelet-based coagulation **PL-25**
J.W.M. Heemskerk (The Netherlands)

- 08.40 – 09.05** Endothelial cell plasticity in inflammatory and pro-thrombotic disease **PL-26**
E. Dejana (Italy)

- 09.05 – 09.30** Mechanistic explanation for platelet contribution to cancer metastasis **PL-27**
D. Stegner (Germany)

- 09.30 – 09.55** May aspirin have a role in cancer prevention and treatment? **PL-28**
C. Patrono (Italy)

SELECTED ABSTRACTS

- 09.55 – 10.10** Inhibition of platelet activation prevents the P-selectin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo **OC-13**
S. Mezouar, R. Darbousset, F. Dignat-George, L. Panicot-Dubois, C. Dubois (France)

- 10.10 – 10.25** Procoagulant phenotypes and F5, F10 and EPCR gene polymorphisms are associated with breast cancer susceptibility **OC-14**
M. Tinholt, M.K. Viken, A.E. Dahm, S. Nyberg, K.K. Sahlberg, A.L. Børresen-Dale, V. Kristensen, R. Kåresen, E. Schlichting, Ø. Garred, G. Skretting, B.A. Lie, P.M. Sandset, N. Iversen (Norway)



PROGRAM

10.30 – 11.00 Coffee Break

11.00 - 13.15 **PLENARY SESSION 8:
TREATMENT OF THROMBOSIS IN CANCER**

Chairs: P.H. Reitsma (The Netherlands), P. Prandoni (Italy)

11.00 – 11.25 Potential antidotes for reversal of new and old anticoagulants **PL-29**
S. Schulman (Canada)

11.25 – 11.50 Overview of treatment of VTE in cancer patients **PL-30**
A.K. Kakkar (UK)

11.50 – 12.15 Perspectives for the use of new anticoagulants for thrombosis treatment **PL-31**
A.Y.Y. Lee (Canada)

12.15 – 12.40 Unsuspected pulmonary embolism in cancer **PL-32**
M. Di Nisio (Italy)

SELECTED ABSTRACTS

12.40 – 12.55 Prescription and long-term use of low-molecular-weight
heparins (LMWH) in routine medical practice for the treatment
of venous thromboembolism in patients with cancer: TROPIQUE a
prospective, french national, multicenter, observational study **OC-15**
D. Farge-Bancel, F. Cajfinger, on behalf of the TROPIQUE investigators (France)

12.55 – 13.10 Outpatient management of cancer-related pulmonary embolism:
analysis of 562 consecutive patients from the EPIPHANY Study **OC-16**
M.A. Vicente, A. Carmona-Bayonas, C. Font, P.J. Fonseca, C. Beato, L. Faez, M. Biosca,
O. Madridano, J. Plasencia, D. Calvo-Temprano, A. Dominguez, P. Arguis, Alejandro Puerta
and R. Otero on behalf of the EPIPHANY Study Investigators. (Spain)

13.15 – 14.30 Lunch

14.30 - 17.30 **POSTER DISCUSSION SESSIONS**

14.30 – 15.45 POSTER DISCUSSION SESSIONS 1, 2 AND 3 (Rooms A, B, and C, see pages 13-17)

15.45 – 16.15 Coffee Break

16.15 – 17.30 POSTER DISCUSSION SESSIONS 4, 5 AND 6 (Rooms A, B, and C, see pages 17-21)

17.30 Meeting closed

POSTER DISCUSSION SESSIONS



Poster Session 1: **EPIDEMIOLOGY I**

Room A

Chairs: L. Iacoviello (Italy), D. Prisco (Italy)

Sunday May 11th, 2014
14.30-15.45

- PO-01** Short-term outcomes of patients with cancer-related pulmonary embolism (PE) according to incidental vs. acute symptomatic events in 562 consecutive patients from the EPIPHANY study
C. Font, A. Carmona-Bayonas, P.J. Fonseca, C. Beato, L. Faez, M.A. Vicente, M. Biosca, O. Madridano, J. Plasencia, D. Calvo-Temprano, A. Dominguez, P. Arguis, A. Puerta and R. Otero on behalf of the EPIPHANY Study Investigators (Spain)
- PO-02** Variation in the risk of venous thromboembolism in people with colorectal cancer: a population based cohort study from England
A.J. Walker, J. West, T.R. Card, D.J. Humes, M.J. Grainge (UK)
- PO-03** Venous thromboembolism in children with cancer: a population-based cohort study
A.J. Walker, M.J. Grainge, T.R. Card, J. West, S. Ranta, J.F. Ludvigsson (UK, Sweden)
- PO-04** Estimating rates of venous thromboembolism in patients with cancer using the Kaplan-Meier and competing-risk approach: insights from the Vienna Cancer and Thrombosis Study
F. Posch, C. Ay, A. Kaider, C. Zielinski, I. Pabinger (Austria)
- PO-05** Descriptive multicentric study of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy
A.J. Muñoz Martín, S.G. Adrián, M.L. Sánchez Lorenzo, V. Pachón Olmos, J.D. Cumplido Burón, J. Martínez-Galán, A.I. Ferrer Pérez, A.B. Rupérez Blanco, P. Jiménez Fonseca (Spain)
- PO-06** High mortality in cancer patients with venous thromboembolism
V. Tagalakis, V. Patenaude, S.R. Kahn, and S. Suissa (Canada)
- PO-07** Surgery and risk of venous thromboembolism in women with cancer
S. Sweetland, A. Balkwill, V. Beral, T. Gathani, J. Green, G. Reeves, on behalf of the Million Women Study Collaborators (UK)
- PO-08** Splanchnic venous thrombosis as a marker of cancer: a Danish nationwide cohort study
K.K. Sogaard, D.K. Farkas, L. Pedersen and H.T. Sørensen (Denmark)
- PO-09** The risk of recurrent venous thrombosis in patients with cancer
J.F. Timp, L.E. Flinterman, A. van Hylckama Vlieg, S. le Cessie, F.R. Rosendaal, S.C. Cannegieter (The Netherlands)
- PO-10** Reliability of diagnosing incidental pulmonary embolism in cancer patients on contrast-enhanced staging CT not intended for pulmonary artery evaluation
P.L. den Exter, L.J.M. Kroft, I.J.C. Hartmann, T. van der Hulle, D. Jiménez, F.A. Klok and M.V. Huisman (The Netherlands, Spain)



POSTER DISCUSSION SESSIONS

- PO-11** Diagnosis of tumor thrombus in the renal vein from an adrenal metastasis of lung cancer with 18FDG PET/CT
A.A. Ciorra, L. Filippi, V. Sciacca, G. Pistillucci, R. Rossi, E. Veltri (Italy)
- PO-12** Prevalence and prognosis of unsuspected pulmonary embolism in cancer patients: a systematic review and meta-analysis
M.P. Donadini, F. Dentali, A. Squizzato, L. Guasti, W. Ageno (Italy)
- PO-13** Prevalence of pulmonary embolism in patients with oncogene addicted advanced lung adenocarcinoma
M. Verso, L. Franco, S. Mosca, M. Fischer, R. Chiari, V. Marconi, L. Paglialunga, G. Agnelli (Italy)
- PO-14** Prevalence of unexpected pulmonary embolism at contrast-enhanced CT scan performed for cancer staging in patients with advanced lung cancer
M. Verso, L. Franco, S. Mosca, M. Fischer, R. Chiari, V. Marconi, L. Paglialunga, G. Agnelli (Italy)
- PO-15** Chemotherapy is associated with the highest risk of VTE in breast cancer patients
A.J. Walker, J. West, T.R. Card, C.C. Kirwan, M.J. Grainge (UK)

Poster Session 2: **MICROPARTICLES & TISSUE FACTOR**

Room B

Chairs: E. Castoldi (The Netherlands), M. Camera (Italy)

Sunday May 11th, 2014
14.30-15.45

- PO-16** Circulating microparticles in cirrhotic patients with hepatocellular carcinoma (HCC) and portal vein thrombosis
E. Campello, A. Zanetto, C.M. Radu, S. Gavasso, L. Spiezia, K. Rodriguez, M. Senzolo, P. Simioni (Italy)
- PO-17** Procoagulant and proangiogenic properties of platelet microparticles (MP) in essential thrombocythemia (ET)
S. Gamba, M. Marchetti, A. Vignoli, L. Russo, C.J. Tartari, G. Finazzi, A. Rambaldi, and A. Falanga (Italy)
- PO-18** Determination of circulating microparticle (MP) cellular origin by flow cytometry in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
C.J. Tartari, M. Marchetti, R. Lacroix, L. Russo, F. Piras, G. Finazzi, A. Rambaldi and A. Falanga (Italy, France)
- PO-19** Pancreatic tumor microvesicles activate platelets
J.E. Geddings, T. M. Getz, Y. Boulaftali, W. Bergmeier, N. Mackman (USA)
- PO-20** The origin and concentration of circulating microparticles differ according to cancer type and evolution
D. Mege, L. Panicot-Dubois, M. Ouaissi, S. Robert, I. Sielezneff, B. Sastre, F. Dignat-George, C. Dubois (France)

POSTER DISCUSSION SESSIONS



- PO-21** TF activity assay on purified plasmatic microparticles using immunomagnetic separation: proof of concept
J. Bez, T. Bouriche, G. Quentin, R. Lacroix, F. Dignat-George, P. Poncelet (France)
- PO-22** Maintenance of ovarian tumour biopsies on a microfluidic chip for measurement of chemotherapy-induced microparticle release and associated procoagulant activity
K. Date, Y. Dou, M. Flynn, S. Haswell, A. Maraveyas, J. Greenman, L. Madden (UK)
- PO-23** Circulating microparticle tissue factor (MP-TF) in glioblastoma multiforme (GBM)
N.S. Key, R.S. Kasthuri, R.L. Bradford, M.G. Piegore, M.T. Sartori, N. Magnus, L. Montermini, J. Rak, D. Schiff, P. Simioni (USA, Italy, Canada)
- PO-24** Prothrombotic and prognostic potential of circulating microparticles in pancreatic cancer: a preliminary prospective evaluation
E. Campello, L. Spiezia, C.M. Radu, S. Rampado, S. Gavasso, B. Woodhams, R. Bardini, P. Simioni (Italy, UK)
- PO-25** The potential of cancer cell lines to release tissue factor-containing microvesicles correlates with tissue factor and PAR2 mRNA levels but not tissue factor protein or surface activity
C. Ettelaie, M. Collier, Y. Xiao, A. Maraveyas (UK)
- PO-26** Tissue factor expression in Danish colon and breast cancer patients and risk of venous thromboembolism
A.G. Ording, M. Vyberg, E. Horváth-Puhó, T.L. Lash, H.T. Sørensen (Denmark, USA)
- PO-27** Preparation and characterization of anti-tissue factor single-chain variable fragment antibody for use in cancer diagnosis
R. Sato (Japan)
- PO-28** Tissue factor is expressed by osteosarcoma and regulates tumor cell invasion
C. Tieken, H.H. Versteeg (The Netherlands)
- PO-29** Tissue factor: a novel therapeutic target against breast cancer stem cells
H. Shaker, H. Harrison, R. Clarke, G. Landberg, N.J. Bundred, H.H. Versteeg, C.C. Kirwan (UK, The Netherlands)
- PO-30** Differential expression of thrombin and tissue factor in neuroendocrine versus adenocarcinoma of the prostate
H. Beltran, J. Chapin, M. Rubin, G. Kaur, S. Tagawa (USA)



POSTER DISCUSSION SESSIONS

Poster Session 3: **BIOMARKERS**

Room C

Chairs: A. Balduini (Italy), M. Mandalà (Italy)

Sunday May 11th, 2014
14.30-15.45

- PO-31** Characteristic subpopulations of childhood acute lymphoblastic leukemia based on intracellular factor XIII-A expression
C. Kiss, K. Gyurina, G. Kiss, Z. Hevessy, L. Csáthy, A. Újfalusi, I. Gáspár, I. Szegedi, B. Scholtz, J. Kappelmayer (Hungary)
- PO-32** Hypercoagulability in cirrhotic patients with hepatocellular carcinoma (HCC) and portal vein thrombosis (PVT)
A. Zanetto, A. Vitale, U. Cillo, K. Rodriguez, M. Fadin, S. Gavasso, C. Radu, P. Zerbinati, F. Farinati, F.P. Russo, G. Germani, P. Burra, P. Simioni, M. Senzolo (Italy)
- PO-33** Fractal dimension (df) as a biomarker of haemostasis and clot structure in cancer
N.A. Davies, N.K. Harrison, M.J. Lawrence, K. Morris, M.R. Brown, D. Pudney, S. Noble, K.M. Hawkins, P.R. Williams, P.A. Evans (UK)
- PO-34** D-dimer levels are significantly elevated in cancer patients with venous thrombosis at time of presentation compared to matched control cancer patients without thrombosis
J. Chapin, P. Christos, M. Mozeih, L. Rochanda, M. DeSancho, A. Ireland, G. Kaur, A. Ocean, H. Liebman, S. Tagawa (USA)
- PO-35** Estimated glomerular filtration rate (eGFR) is an easy predictor of venous thromboembolism in cancer patients undergoing platinum-based chemotherapy
P. Ferroni, F. Guadagni, A. Laudisi, M. Vergati, S. Riondino, G. Davì, M. Roselli (Italy)
- PO-36** Application of thromboelastography parameters for the prediction of venous thromboembolism in cancer patients receiving chemotherapy
V.A. Sukhanov, O.Y. Petrova (Russian Federation)
- PO-37** Monocyte count is a thrombosis marker: a pilot study
A. Cafolla, M.C. Cursano, U. De Faveri, D. Rossini, D. Pasqualetti, F. Longo, E. Baldacci, R. Foa (Italy)
- PO-38** Angiogenic and procoagulant factors in plasma of brain tumour patients treated with bevacizumab
A. Antenucci, A. Pace, C. Mandoj, V. Villani, I. Sperduti and L. Conti (Italy)
- PO-39** Effect of LMWH (Tinzaparin) post surgery in gynaecological patients: a study of anti-Xa activity levels
N. Ibrahim, L. Norris, S. O'Toole, N. Gleeson (Ireland)
- PO-40** Thromboelastography as a tool for detecting hypercoagulability in gynaecological cancer patients undergoing surgery
N. Ibrahim, L. Norris, N. Nikolov, N. Gleeson (Ireland)

POSTER DISCUSSION SESSIONS



- PO-41** Clotting changes in patients with gastrointestinal tract cancer: an exploratory study
E. de Meis, E.A. Machado, D.M. Mizurini, A.C. Leal, M.T. Guedes, V.R. Pinheiro, R.M. Fontenele, J.P. de Jesus, D.D.B. Lauzin, R.Q. Monteiro (Brazil)
- PO-42** The thrombotic response to surgery is upregulated in aggressive breast cancer phenotypes
H. Shaker, N.J. Bundred, J. Castle, G. Landberg, C.C. Kirwan (UK)
- PO-43** Association of soluble CD40 ligand and thrombospondin-1 with cancer-associated venous thromboembolism
J.Riedl, A. Kaider, F. Posch, S. Koder, E.M. Reitter, C. Marosi, C. Zielinski, I. Pabinger, C. Ay (Austria)
- PO-44** sEPCR influences innate immune response in ovarian cancer by decreasing of natural killer and TH17 helper cells population
A. Dalel, A.T. Hamda, A.F. Halema, S. Besbes, M. Shahsoltan, T. Amu, P.L. Eric, J. Soria, M. Massoud (France)

Poster Session 4: **EPIDEMIOLOGY II**

Room A

Chairs: L. De Marco (Italy), P. Simioni (Italy)

Sunday May 11th, 2014
16.15-17.30

- PO-45** Comorbidities in patients with cancer and risk of venous thromboembolism
O. Königsbrügge, F. Lötsch, C. Zielinski, I. Pabinger, C. Ay (Austria)
- PO-46** Preliminary report on the efficacy of the use of the secure SharePoint reminder system to improve rates of inferior vena cava filter retrieval: a quality improvement project using the Veterans Administration electronic medical record (EMR)
D.A. Mobarek, J. Elamm, N. Bade, A. Aggarwal, S. Tabar, D. Bentt, C. Faselis, F. Rickles (USA)
- PO-47** The influence of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability
M. Chaari, I. Ayadi, E. Lefkou, P. Vandreden, A. Rousseau, H. Ketatni, V. Galea, F. Sidibe, L. Ghorbal, J. Gligorov, J.P. Lotz, I. Elalamy, G.T. Gerotziakas (France, Tunisia)
- PO-48** Thrombogenic risk profile among patients undergoing major cancer surgery
K. Burbury, A. Woolley, M. Collins, A. Heriot, K. Kenchington, D. Westerman, R. Dauer, B. Riedel (Australia)
- PO-49** External validation of current VTE risk prediction scores for patients with solid cancer in an ongoing prospective multicenter cohort study
N. van Es, S.M. Bleker, M. Di Nisio, P.W. Kamphuisen, H.M. Otten, I. Mahé, A. Stépanian, G. Cesarman, P. Nanayakkara, H.R. Büller (The Netherlands, Italy, France, Mexico)



POSTER DISCUSSION SESSIONS

- PO-50** A risk assessment model for the identification of Cushing's syndrome patients at risk for venous thromboembolism
L. Mazzai, M.T. Sartori, F. Noventa, A. Casonato, V. Daidone, M. Zilio, F. Ceccato, M. Barbot, L. Schiavon, M. Boscaro, C. Scaroni (Italy)
- PO-51** Clinical presentation and outcome in patients with pulmonary embolism with and without cancer
C. Becattini, G. Agnelli, M. Biancardi, A.B. Scardovi, O. Serafini, F. Casazza (Italy)
- PO-52** Locally advanced colorectal cancers result in a hypercoagulable state: implications for extended post-operative prophylaxis
H.W. Clouston, H. Shaker, S. Duff, C.C. Kirwan (UK)
- PO-53** Outcomes after inferior vena cava filter placement in cancer patients hospitalized for acute venous thromboembolism
T. Wun, A. Brunson, G. Ho, R.H. White (USA)
- PO-54** The diagnosis of cancer following a venous thromboembolic event
R. Kasbar, M. Grainge, R. Hubbard, A. Walker (UK)
- PO-55** Cerebral venous thrombosis (CTV), retrospective study in oncologic patients
T. Ramalhão, A. Iashchuk, J. Moutinho, M.J. Milheiro, M.L. Santos (Portugal)
- PO-56** Splanchnic vein thrombosis (SVT) and extra-abdominal thromboembolism (EAT) as differential entities in pancreatic cancer
L. Sande, E. Martínez, V. Arrazubi, A.I. Córdoba, P. Novas, M. Múgica, J.D. Cacho, M. Muñiz, A. Arévalo, P. Martínez del Prado (Spain)
- PO-57** Modeling the individual risk of thrombosis in oncology
A.J. Muñoz Martín, J.C. Souto, V. Castellón Rubio, J. Calzas Rodríguez, M. Salgado Fernández, V. Pachón Olmos, B. Morejón Huerta, R.I. Luque Caro, M. Martín Jiménez, J. Manuel Soria (Spain)
- PO-58** The burden of venous thromboembolism on the cancer patient experience: a qualitative study
S. Noble, S. Seaman, A. Nelson (UK)

POSTER DISCUSSION SESSIONS



Poster Session 5: **PATHOGENESIS AND MANAGEMENT OF HEMOSTATIC SYSTEM ALTERATIONS**

Room B

Chairs: E. De Candia (Italy), G. Taraboletti (Italy)

Sunday May 11th, 2014
16.15-17.30

- PO-59** Doxorubicin treatment of tumour cells increases procoagulant activity of media
K. Date, J. Greenman, A. Maraveyas, L. Madden (UK)
- PO-60** Targeting phosphatidylethanolamine on tumour cells using duramycin
L. Broughton, A. Maraveyas and L. Madden (UK)
- PO-61** FLT3-ITD mutation status is not associated with enhanced procoagulant activity in monocytic leukemia cell lines
R. Hudák, I. Beke Debreceni, G. Szabó Gál, P. Antal-Szalmás, J. Kappelmayer (Hungary)
- PO-62** Characterization of a novel anti insoluble fibrin clot monoclonal antibody for cancer stromal targeting (CAST) diagnosis
Y. Hisada, M. Yasunaga, S. Hanaoka, S. Saijou, T. Sugino, A. Tsuji, T. Saga, K. Tsumoto, S. Manabe, J. Kuroda, J. Kuratsu, and Y. Matsumura (Japan)
- PO-63** Identification of "Effector Protease Receptor-1a (EPR-1a)" a binding site for the coagulation factor Xa on the membrane of breast cancer cell line MDA-MB231
S. Mirshahi, S.Q. Mirshahi, S. Besbes, S. Le Marchand, M. Mirshahi, J. Soria (France)
- PO-64** E-selectin expressed by melanoma cells may be involved in cellular interactions with leukocytes via PSGL-1
B. Nagy Jr., L. Vízkeleti, D. Hamar, G. Szabó Gál, P. Nagy, I. Balogh, M. Balázs, J. Kappelmayer (Hungary)
- PO-65** Normal human platelet extracts induce growth, migration and invasion and drug resistance in human hepatocellular carcinoma in vitro
B.I. Carr, A. Cavallini, R. D'Alessandro, M.G. Refolo, C. Lippolis, A. Mazzocca, C. Messa (Italy)
- PO-66** Increased polymorphisms of platelet reactivity associates with cancer stage and prognosis in cancer patients
I. Vasilenko, A. Matveeva, V. Metelin, P. Poljakov, O. Bichenkov, A. Balkanov (Russian Federation)
- PO-67** Increased platelet thrombus formation under flow condition in myeloproliferative neoplasms (MPNs)
A. Vignoli, C. Giaccherini, S. Tassarolo, M. Marchetti, P.E. van der Meijden, F. Swieringa, H. ten Cate, G. Finazzi, A. Rambaldi, J.W.M. Heemskerk and A. Falanga (Italy, The Netherlands)
- PO-68** Impact of endothelial protein C receptor (A6936G) haplotype on thrombotic events in acute myeloid leukemia
S. Besbes, H. Althawadi, H. Alfarsi, S. Mirshahi, R. Tang, F. Fava, A. Therwath, I. Ghedira, J. Soria, J.P. Marie, M. Mirshahi (Qatar, France, Tunisia)



POSTER DISCUSSION SESSIONS

- PO-69** Clinical course and hemostasis strategies in patients with severe hemophilia A and diffuse large B-cell lymphoma (DLBCL): a single center experience and review of the literature
S.C. Rutherford, P. Martin, W. Tam, M.T. DeSancho, and J. Chapin (USA)
- PO-70** Prophylactic and therapeutic platelets transfusion for hypoproliferative thrombocytopenia in myelotoxic chemotherapy: a single centre experience
P. Radossi, L. Candiotto, N. Maschio, R. Sartori, E. Scarpa, C. Tassinari and G. Tagariello (Italy)
- PO-71** Intensive transfusion support in acute promyelocytic leukemia
G. Tagariello, L. Candiotto, F. Mosna, P.M. Stefani, R. Sartori, P. Radossi, F. Gherlinzoni (Italy)
- PO-72** Thrombophilia and DIC during chemotherapy in ovarian cancer patients
A.V. Vorobiev, A.D. Makatsaria (Russian Federation)
- PO-73** Complement activation in cancer-associated venous thromboembolism (VTE): a pilot study
E.A. Peterson, A.Y.Y. Lee, H. Lim, A. Ludlow, V. Lei and E.M. Conway (Canada)

Poster Session 6: **NEW AND OLD ANTICOAGULANTS**

Room C

Chairs: V. De Stefano (Italy), S. Siragusa (Italy)

Sunday May 11th, 2014
16.15-17.30

- PO-74** The REALITY of cancer-associated thrombosis treatment
J.-F. Baurain, K.S.G. Jie, A. Mellema, I. Timberg,
R.M. Molenaar-Overmeer (Belgium, The Netherlands, Denmark, Sweden)
- PO-75** Attitudes of cancer associated thrombosis patients to the novel oral anticoagulants: insights from qualitative interviews
S. Noble, S. Seaman, A. Nelson (UK)
- PO-76** Phase I feasibility study and biomarker analysis of concurrent fondaparinux (F) with standard chemotherapy (CT) in advanced stage IV non-small cell lung cancer (NSCLC)
F. Robert, D.J. Mooney, M. Jerome, D. Miley, S. Zhu (USA)
- PO-77** ALICAT: Anticoagulation Length In Cancer Associated Thrombosis - A mixed-methods feasibility study
S. Noble, J.D. Smith, J. Baillie, T. Baglin, G.O. Griffiths, A. Casbard, D. Cohen, D. Fitzmaurice, K. Hood, P. Rose, A. Cohen, M. Johnson, A. Maraveyas, J. Bell, H. Toone, A. Nelson (UK)
- PO-78** Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism
A. Young, J. Phillips, A. Marshall, J. Grumett, J.A. Dunn, S. Lowe, O. Chapman and A. Lokare (UK)

POSTER DISCUSSION SESSIONS



- PO-79** A survey of the current practice in anticoagulating the subsegmental pulmonary embolism in cancer patients: disparities among different medical specialties.
G. Bozas, W.Y. Lim, S. Noble, S. Hart, A. Maraveyas (UK)
- PO-80** Influence of cancer on the efficacy and safety of dabigatran vs warfarin for the acute and extended treatment of venous thromboembolism
S. Schulman, H. Eriksson, S.Z. Goldhaber, A. Kakkar, C. Kearon, S. Schellong, M. Feuring, J. Friedman and J. Kreuzer (Canada, Sweden, USA, UK, Germany)
- PO-81** Patterns of VTE treatment with rivaroxaban in cancer patients: results of the prospective Dresden NOAC registry (NCT01588119)
F. Michalski, F. Ebertz, V. Gelbricht, K. Förster, C. Thieme, L. Tittl, C. Köhler, S. Werth, J. Beyer-Westendorf (Germany)
- PO-82** Novel Oral Anticoagulants for Patients with Venous Thromboembolism and Active Cancer: a Systematic Review and Meta-Analysis
M.C. Vedovati, F. Germini, G. Agnelli, C. Becattini (Italy)
- PO-83** Familial antithrombin deficiency and risk of VTE in pregnant women receiving LMW heparin prophylaxis
I. Dybedal, L. Borge, J.B. Hansen, P. Majak, A.M. Njaastad, E. Smedvig, U. Abildgaard (Norway)
- PO-84** Peak anti-Xa levels following LMWH (tinzaparin) prophylaxis in gynaecological cancer patients post-surgery
F. Abu Saadeh, S. O'Toole, N. Gleeson, L. Norris (Ireland)
- PO-85** Dose escalation of low molecular weight heparin in cancer patients with recurrent venous thromboembolism
R. Ihaddadene, G. Le Gal, M. Carrier (Canada, France)
- PO-86** Does the extended thromboprophylaxis help to reduce the incidence of venous thromboembolism in gynaecological cancer patients?
N. Ibrahim, L. Norris, S. O'Toole, T. McHugh, F. Abu Saadeh, N. Gleeson (Ireland)
- PO-87** Inhibition of thrombin generation by antithrombin-dependent antithrombotic agents (enoxaparin, fondaparinux) and direct anti-Xa anti-coagulant (Apixaban) on human pancreatic (BXPc3) and human breast cancer cells (MCF7)
A. Rousseau, P. Van Dreden, H. Mokrani, M. Hatmi, I. Elalamy, and G.T. Gerotziafas (France)
- PO-88** Occurrence of intracranial bleeding in patients (pts) requiring low molecular weight heparin (LMWH) for treatment of thromboembolic events and suffering from brain metastases treated with radiotherapy
F.V. Vitale, P. Romeo, M. Raffaele, G. Bellocchio, A. Russo, R. Briguglio, F. Ferraù (Italy)



AUTHOR INDEX

A

Abildgaard, U. PO-83
 Abish, S. OC-01
 Abu Saadeh, F. PO-84, PO-86
 Adrián, S.G. PO-05
 Ageno, W. OC-02, PO-12
 Aggarwal, A. PO-46
 Agnelli, G. PL-23, PO-13, PO-14,
 PO-51, PO-82
 Albady, H. OC-08
 Alexander, M. OC-12
 Alfarsi, H. PO-68
 Althawadi, H. PO-68
 Amu, T. PO-44
 Antal-Szalmás, P. PO-61
 Antenucci, A. PO-38
 Aprile, L. OC-09
 Arévalo, A. PO-56
 Arguis, P. OC-16, PO-01
 Arrazubi, V. PO-56
 Ay, C. PL-07, OC-05, PO-04,
 PO-43, PO-45
 Ayadi, I. PO-47

B

Bade, N. PO-46
 Baglin, T. PO-77
 Baillie, J. PO-77
 Balázs, M. PO-64
 Baldacci, E. PO-37
 Balkanov, A. PO-66
 Balkwill, A. PO-07
 Ball, D. OC-12
 Balogh, I. PO-64
 Baratè, C. OC-09
 Barbot, M. PO-50
 Barcella, L. OC-07

Bardini, R. PO-24
 Baurain, J.-F. PO-74
 Beato, C. OC-16, PO-01
 Becattini, C. PO-51, PO-82
 Beke Debreceni, I. PO-61
 Bell, J. PO-77
 Bellocco, G. PO-88
 Belting, M. PL-16
 Beltran, H. PO-30
 Benrt, D. PO-46
 Beral, V. PO-07
 Bergmeier, W. PO-19
 Besbes, S. PO-44, PO-63, PO-68
 Beyer-Westendorf, J. PO-81
 Bez, J. PO-21
 Biancardi, M. PO-51
 Bichenkov, O. PO-66
 Biosca, M. OC-16, PO-01
 Bleker, S.M. PO-49
 Bocchia, M. OC-09
 Borge, L. PO-83
 Børresen-Dale, A.L. OC-14
 Boscaro, M. PO-50
 Bosi, A. OC-09
 Boulaftali, Y. PO-19
 Bouriche, T. PO-21
 Bozas, G. PO-79
 Bradford, R.L. PO-23
 Briguglio, R. PO-88
 Broughton, L. PO-60
 Brown, M.R. PO-33
 Brunson, A. PO-53
 Büller, H.R. PO-49
 Bundred, N.J. OC-08, PO-29,
 PO-42
 Bura-Riviere, A. OC-06
 Burbury, K. OC-12, PO-48
 Burra, P. PO-32

C

Cacho, J.D. PO-56
 Cafolla, A. PO-37
 Cajfinger, F. OC-15
 Calvo-Temprano, D. OC-16,
 PO-01
 Calzas Rodríguez, J. PO-57
 Campello, E. OC-03, PO-16,
 PO-24
 Candi, V. OC-09
 Candiotto, L. PO-70, PO-71
 Cannegieter, S.C. PO-09
 Card, T.R. PO-02, PO-03, PO-15
 Carmona-Bayonas, A. OC-16,
 PO-01
 Carr, B.I. PO-65
 Carrier, M. OC-11, PO-85
 Casazza, F. PO-51
 Casbard, A. PO-77
 Casonato, A. PO-50
 Castellón Rubio, V. PO-57
 Castle, J. PO-42
 Cavallini, A. PO-65
 Ceccato, F. PO-50
 Celio, L. OC-07
 Cesарman, G. PO-49
 Chaari, M. PO-47
 Chapin, J. OC-04, PO-30, PO-34,
 PO-69
 Chapman, O. PO-78
 Chiari, R. PO-14, PO-13
 Christos, P. OC-04, PO-34
 Ciccarino, P. OC-03
 Cillo, U. PO-32
 Ciorra, A.A. PO-11
 Clarke, R. PO-29
 Clouston, H.W. PO-52

AUTHOR INDEX



Cohen, A. PO-77
Collier, M. PO-25
Collins, M. PO-48
Conti, L. PO-38
Conway, E.M. PO-73
Córdoba, A.I. PO-56
Csáthy, L. PO-31
Cumplido Burón, J.D. . . . PO-05
Cursano, M.C. PO-37

D

D'Alessandro, R. PO-65
Dahm, A.E. OC-14
Daidone, V. PO-50
Dalel, A. PO-44
Darbousset, R. OC-13
Date, K. PO-22, PO-59
Dauer, R. PO-48
Davì, G. PO-35
Davies, N.A. PO-33
De Braud, F. OC-07
De Faveri, U. PO-37
de Jesus, J.P. PO-41
De Majo, F. OC-09
de Meis, E. PO-41
Debourdeau, P. OC-06
Defina, M. OC-09
Dejana, E. PL-26
Della Puppa, A. OC-03
den Exter, P.L. PO-10
Dentali, F. OC-02, PO-12
DeSancho, M. PO-34, PO-69
Di Micco, P. OC-06
Di Nisio, M. PL-32, PO-49
Dierrich, K. OC-01
Dignat-George, F. PL-06,
OC-13, PO-20, PO-21

Dominguez, A. OC-16, PO-01
Donadini, M.P. PO-12
Dou, Y. PO-22
Dubois, C. OC-13, PO-20
Duff, S. PO-52
Dunn, J.A. PO-78
Dybedal, I. PO-83

E

Ebertz, F.J. PO-81
El Nemer, W. PL-18
Elalamy, I. PO-47, PO-87
Elamm, J. PO-46
Eric, P.L. PO-44
Eriksson, H. PO-80
Ettelaie, C. PO-25
Evans, P.A. PO-33

F

Fadin, M. PO-32
Faez, L. OC-16, PO-01
Falanga, A. OC-07, PO-17,
PO-18, PO-67
Farge-Bancel, D. OC-06, OC-15
Farinati, F. PO-32
Farkas, D.K. PO-08
Faselis, C. PO-46
Fava, F. PO-68
Federici, A.B. PL-10
Ferraù, F. PO-88
Ferrer Pérez, A.I. PO-05
Ferroni, P. PO-35
Feuring, M. PO-80
Filippi, L. PO-11
Finazzi, G. PO-17, PO-18, PO-67
Fischer, M. PO-13, PO-14
Fitzmaurice, D. PO-77

Flinterman, L.E. PO-09
Flynn, M. PO-22
Foa, R. PO-37
Fonseca, P. J
OC-16, PO-01
Font, C. OC-16, PO-01
Fontenele, R.M. PO-41
Förster, K. PO-81
Franco, L. PO-13, PO-14
Friedman, J. PO-80

G

Galea, V. PO-47
Galimberti, S. OC-09
Gamba, S. PO-17
Garred, Ø. OC-14
Gáspár, I. PO-31
Gasparini, G. OC-07
Gathani, T. PO-07
Gavasso, S. PO-16, PO-24,
PO-32
Geddings, J.E. PO-19
Gelbricht, V. PO-81
Germani, G. PO-32
Germi, F. PO-82
Gerotziakas, G.T. PO-47, PO-87
Getz, T.M. PO-19
Ghedira, I. PO-68
Gherlinzoni, F. PO-71
Ghorbal, L. PO-47
Giaccherini, C. OC-07, PO-67
Gleeson, N. PO-39, PO-40,
PO-84, PO-86
Gligorov, J. PO-47
Goldhaber, S.Z. PO-80
Gozzetti, A. OC-09
Gozzini, A. OC-09



AUTHOR INDEX

Grainge, M. PO-02, PO-03,
PO-15, PO-54
Green, J. PO-07
Greenman, J. PO-22, PO-59
Griffiths, G.O. PO-77
Grumett, J. PO-78
Guadagni, F. PO-35
Guasti, L. PO-12
Guedes, M.T. PO-41
Gyurina, K. PO-31

H

Halema, A.F. PO-44
Halton, J. OC-01
Hamar, D. PO-64
Hamda, A.T. PO-44
Hanaoka, S. PO-62
Hansen, J.B. PO-83
Harrison, H. PO-29
Harrison, N.K. PO-33
Hart, S. PO-79
Hartmann, I.J.C. PO-10
Haswell, S. PO-22
Hatmi, M. PO-87
Hawkins, K.M. PO-33
He, J. OC-10
Heemskerck, J.W.M. PL-25, PO-67
Heriot, A. PO-48
Hevessy, Z. PO-31
Hisada, Y. PO-62
Ho, G. PO-53
Hood, K. PO-77
Horváth-Puhó, E. PO-26
Hubbard, R. PO-54
Hudák, R. PO-61
Huisman, M.V. PL-01, PO-10
Humes, D.J. PO-02

I

Iashchuk, A. PO-55
Ibrahim, N. PO-39, PO-40,
PO-86
Ihaddadene, R. PO-85
Ireland, A. OC-04, PO-34
Israels, S.J. OC-01
Iversen, N. OC-14

J

Jerome, M. PO-76
Jie, K.S.G. PO-74
Jiménez Fonseca, P. PO-05
Jiménez, D. PO-10
Johnson, M. PO-77

K

Kahn, S.R. PO-06
Kaider, A. PO-04, PO-43
Kakkar, A.K. PL-30, PO-80
Kamphuisen, P.W. PL-09, PO-49
Kappelmayer, J. PO-31, PO-61,
PO-64
Kåresen, R. OC-14
Kasbar, R. PO-54
Kasthuri, R.S. PO-23
Kaur, G. OC-04, PO-30, PO-34
Kearon, C. PO-80
Kenchington, K. PO-48
Keratni, H. PO-47
Key, N.S. PO-23
Khorana, A.A. PL-05
Kirsá, S. OC-12
Kirwan, C.C. OC-08, PO-15,
PO-29, PO-42, PO-52
Kiss, C. PO-31
Klok, F.A. PO-10

Koder, S. PO-43
Köhler, C. PO-81
Königsbrügge, O. PO-45
Kreuzer, J. PO-80
Kristensen, V. OC-14
Kroft, L.J.M. PO-10
Kuratsu, J. PO-62
Kuroda, J. PO-62
Kyrle, P.A. PL-02

L

Labianca, R. OC-07
Lacroix, R. PO-18, PO-21
Landberg, G. OC-08, PO-29,
PO-42
Lash, T.L. PO-26
Laudisi, A. PO-35
Lauzin, D.D.B. PO-41
Lawrence, M.J. PO-33
le Cessie, S. PO-09
Le Gal, G. OC-11, PO-85
Le Marchand, S. PO-63
Leal, A.C. PO-41
Lee, A.Y.Y. PL-31, PO-73
Lefkou, E. PO-47
Lei, V. PO-73
Levi, M.M. PL-12
Levine, M.N. PL-22
Lie, B.A. OC-14
Liebman, H. PL-11, PO-34
Lim, H. PO-73
Lim, W.Y. PO-79
Lin, T. OC-10
Lipe, B. OC-10
Lippolis, C. PO-65
Lo Coco, F. PL-19
Lokare, A. PO-78

AUTHOR INDEX



Longo, F. PO-37
 Lörsch, F. PO-45
 Lotz, J.P. PO-47
 Lowe, S. PO-78
 Ludlow, A. PO-73
 Ludvigsson, J.F. PO-03
 Luque Caro, R.L. PO-57
 Lyman, G.H. PL-21

M

Machado, E.A. PO-41
 Mackman, N. PO-19
 MacManus, M. OC-12
 Madden, L. PO-22, PO-59,
 PO-60
 Madridano, O. OC-16, PO-01
 Magnus, N. PO-23
 Mahé, I. PO-49
 Majak, P. PO-83
 Makatsaria, A.D. PO-72
 Manabe, S. PO-62
 Mandalà, M. OC-07
 Mandoj, C. PO-38
 Mantiero, M. OC-02
 Manuel Soria, J. PO-57
 Maraveyas, A. PO-22, PO-25,
 PO-59, PO-60, PO-77, PO-79
 Marchetti, M. OC-07, PO-17,
 PO-18, PO-67
 Marconi, V. PO-13, PO-14
 Marie, J.P. PO-68
 Marosi, C. PO-43
 Marshall, A. PO-78
 Martín Jiménez, M. PO-57
 Martín, P. PO-69
 Martínez, E. PO-56
 Martínez del Prado, P. PO-56
 Martínez-Galán, J. PO-05

Maschio, N. PO-70
 Masci, G. OC-07
 Massoud, M. PO-44
 Matsumura, Y. PO-62
 Matveeva, A. PO-66
 Mazzai, L. PO-50
 Mazzocca, A. PO-65
 McHugh, T. PO-86
 Mege, D. PO-20
 Mellemgaard, A. PO-74
 Merelli, B. OC-07
 Messa, C. PO-65
 Metelin, V. PO-66
 Mezouar, S. OC-13
 Michalski, F. PO-81
 Mikhail, M. OC-04
 Miley, D. PO-76
 Milheiro, M.J. PO-55
 Mirshahi, M. PO-63, PO-68
 Mirshahi, S. PO-63, PO-68
 Mitchell, L.G. OC-01
 Mizurini, D.M. PO-41
 Mobarek, D.A. PO-46
 Mokrani, H. PO-87
 Molenaar-Overmeer, R.M. PO-74
 Monreal, M. OC-06, PL-04
 Monteiro, R.Q. PO-41
 Montermini, L. PO-23
 Mooney, D.J. PO-76
 Morejón Huerta, B. PO-57
 Moretto, P. OC-11
 Morris, K. PO-33
 Mosca, S. PO-13, PO-14
 Mosna, F. PO-71
 Moutinho, J. PO-55
 Mozeih, M. PO-34
 Múgica, M. PO-56

Muñiz, M. PO-56
 Muñoz Martin A.J. PO-05, PO-57
 Muzzolon, J. OC-02

N

Nadir, Y. PL-15
 Nagy Jr., B. PO-64
 Nagy, P. PO-64
 Nanayakkara, P. PO-49
 Nanus, D. OC-04
 Nelson, A. PO-58, PO-75, PO-77
 Nicholson, S.L. OC-08
 Nikolov, N. PO-40
 Njaastad, A.M. PO-83
 Noble, S. PL-24, PO-33, PO-58,
 PO-75, PO-77, PO-79
 Norris, L. PO-39, PO-40, PO-84,
 PO-86
 Novas, P. PO-56
 Noventa, F. PO-50
 Nyberg, S. OC-14

O

O'Toole, S. PO-39, PO-84, PO-86
 Ocean, A. PO-34
 Ording, A.G. PO-26
 Ornstein, D. OC-10
 Otero, R. OC-16, PO-01
 Otten, H.M. PO-49
 Ouaisi, M. PO-20

P

Pabinger, I. OC-05, PO-04,
 PO-43, PO-45
 Pace, A. PO-38
 Pachón Olmos, V. PO-05, PO-57
 Paglialunga, L. PO-13, PO-14
 Panicot-Dubois, L. OC-13, PO-20



AUTHOR INDEX

- Pasqualetti, D. PO-37
Pastore, A. OC-02
Parenaude, V. PO-06
Patrino, C. PL-28
Pedersen, L. PO-08
Peterson, E.A. PO-73
Perrini, M. OC-09
Petrova, O.Y. PO-36
Phillips, J. PO-78
Piegore, M.G. PO-23
Pinheiro, V.R. PO-41
Pinotti, G. OC-02
Piras, F. OC-07, PO-18
Pistillucci, G. PO-11
Plasencia, J. OC-16, PO-01
Poljakov, P. PO-66
Poncelet, P. PO-21
Posch, F. PO-04, PO-43
Pritchard, S. OC-08
Puccetti, L. OC-09
Pudney, D. PO-33
Puerta, A. OC-16, PO-01
- Q**
- Quentin, G. PO-21
- R**
- Radossi, P. PO-70, PO-71
Radu, C.M. OC-03, PO-16,
PO-24, PO-32
Raffaele, M. PO-88
Rak, J. S1 (Simon Karpatkin
Memorial Lecture), PO-23
Ramalhão, T. PO-55
Rambaldi, A. PO-17, PO-18,
PO-67
Rampado, S. PO-24
Ranta, S. PO-03
Raspadori, D. OC-09
Reeves, G. PO-07
Refolo, M.G. PO-65
Reitter, E.M. PO-43
Reyes, R. OC-10
Rickles, F.R. PO-46
Riedel, B. PO-48
Riedl, J. PO-43
Riondino, S. PO-35
Robert, F. PO-76
Robert, S. PO-20
Rochanda, L. PO-34
Rodostits, T. OC-01
Rodriguez, K. PO-16, PO-32
Rodriguez-Beltrán, E.M. OC-06
Roengvoraphoj, M. OC-10
Romeo, P. PO-88
Rose, P. PO-77
Roselli, M. PO-35
Rosendaal, F.R. PO-09
Rossi, R. PO-11
Rossini, D. PO-37
Rousseau, A. PO-47, PO-87
Rubin, M. PO-30
Ruf, W. PL-14
Rupérez Blanco, A.B. PO-05
Russo, A. PO-88
Russo, F.P. PO-32
Russo, L. PO-17, PO-18
Rutherford, S.C. PO-69
- S**
- Saga, T. PO-62
Sahlberg, K.K. OC-14
Saijou, S. PO-62
Salgado Fernández, M. PO-57
Sánchez Lorenzo, M.L. PO-05
Sande, L. PO-56
Sandset, P.M. OC-14
Santoro, A. OC-07
Santos, M.L. PO-55
Sarmiento, R. OC-07
Sartori, M.T. OC-03, PO-23,
PO-50
Sartori, R. PO-70, PO-71
Sastre, B. PO-20
Sato, R. PO-27
Scappini, B. OC-09
Scardovi, A.B. PO-51
Scaroni, C. PO-50
Scarpa, E. PO-70
Scarpini, F. OC-09
Schellong, S. PO-80
Schiavon, L. PO-50
Schiff, D. PO-23
Schlichting, E. OC-14
Scholtz, B. PO-31
Schulman, S. PL-29, PO-80
Sciaccia, V. PO-11
Scienza, R. OC-03
Seaman, S. PO-58, PO-75
Senzolo, M. PO-16, PO-32
Serafini, O. PO-51
Shahsoltan, M. PO-44
Shaker, H. OC-08, PO-29,
PO-42, PO-52
Shereck, E. OC-01
Sicurezza, A. OC-09
Sidibe, F. PO-47
Sielezneff, I. PO-20
Simioni, P. OC-03, PO-16,
PO-23, PO-24, PO-32
Skretting, G. OC-14
Smedvig, E. PO-83
Smith, J.D. PO-77

AUTHOR INDEX



Søgaard, K.K. PO-08
 Solomon, B. OC-12
 Sørensen, H.T. . . . PO-08, PO-26
 Soria, J. . . . PO-44, PO-63, PO-68
 Souto, J.C. PO-57
 Spavor, M. OC-01
 Sperduti, I. PO-38
 Spiezia, L. OC-03, PO-16, PO-24
 Squizzato, A. PO-12
 Stefani, P.M. PO-71
 Stegner D. PL-27
 Strépanian, A. PO-49
 Sugino, T. PO-62
 Suissa, S. PO-06
 Sukhanov, V.A. PO-36
 Sweetland, S. PO-07
 Swieringa, F. PO-67
 Szabó Gál, G. . . . PO-61, PO-64
 Szegedi, I. PO-31

T

Tabar, S. PO-46
 Tagalakis, V. PO-06
 Tagariello, G. . . . PO-70, PO-71
 Tagawa, S. OC-04, PO-30,
 PO-34
 Tam, W. PO-69
 Tang, R. PO-68
 Tartari, C.J. OC-07, PO-17,
 PO-18
 Tassinari, C. PO-70
 ren Care, H. PO-67
 Tessarolo, S. PO-67
 Thaler, J. OC-05
 Therwath, A. PO-68
 Thieme, C. PO-81
 Tieken, C. PO-28
 Timberg, I. PO-74

Timp, J.F. PO-09
 Tinholt, M. OC-14
 Tittl, L. PO-81
 Tondini, C. OC-07
 Toone, H. PO-77
 Trujillo-Santos, J. OC-06
 Tsuji, A. PO-62
 Tsumoto, K. PO-62

U

Újfalusi, A. PO-31

V

Vacca, A. PL-17
 van der Hulle, T. PO-10
 van der Meijden, P.E. . . . PO-67
 Van Dreden, P. . . . PO-47, PO-87
 van Es, N. PO-49
 van Hylckama Vlieg, A. . . PO-09
 Vasilenko, I. PO-66
 Vedovati, M.C. PO-82
 Veltri, E. PO-11
 Vergati, M. PO-35
 Verso, M. PO-13, PO-14
 Versteeg, H.H. . . . PL-13, PO-28,
 PO-29
 Verzeroli, C. OC-07
 Vicente, M.A. OC-16, PO-01
 Vignoli, A. OC-07, PO-17, PO-67
 Viken, M.K. OC-14
 Villani, V. PO-38
 Visonà, A. OC-06
 Vitale, A. PO-32
 Vitale, F.V. PO-88
 Vízkeleti, L. PO-64
 Vorobiev, A.V. PO-72
 Vyberg, M. PO-26

W

Walker, A.J. PO-02, PO-03,
 PO-15, PO-54
 Weitz, I.C. PL-20
 Werth, S. PO-81
 West, J. . . . PO-02, PO-03, PO-15
 Westerman, D. PO-48
 White, R.H. PL-03, PO-53
 Williams, P.R. PO-33
 Woodhams, B. PO-24
 Woolley, A. PO-48
 Wun, T. PO-53

X

Xiao, Y. PO-25

Y

Yacoub, A. OC-10
 Yasui, Y. OC-01
 Yasunaga, M. PO-62
 Yong, J. OC-01
 Young, A. PO-78

Z

Zalunardo, B. OC-06
 Zanetto, A. PO-16, PO-32
 Zeltser, D. OC-06
 Zerbini, P. PO-32
 Zhu, S. PO-76
 Zielinski, C. PO-04, PO-43,
 PO-45
 Zilio, M. PO-50
 Zwicker, J.I. PL-08



GENERAL INFORMATION

Meeting venue

The Conference takes place in Bergamo at the
Seminario Vescovile "Giovanni XXIII"
Via Arena, 11 - Bergamo, Città Alta (Upper Town)

Organizing Secretariat

Servizi C.E.C. Srl

Servizi Congressuali ed Eventi Culturali
Via Verdi 18 - 24121 Bergamo - Italy
On site phone +39.035 286307
e-mail: info@icthic.com

Registration desk

The registration desk is located in the entrance hall of the Seminario Vescovile.
It is staffed continuously every day of the conference. The staff is at your disposal for any information. Facilities available at the registration desk include:

On-site registration

Fees for on-site registration are:

- Delegate euro 655
- Student euro 150
- Accompanying person euro 160

Message boards

Any late change in the program of the conference or personal messages will be notified here.

Telephone and fax

Available on request.

Computing, printing and xeroxing

Available on request.

Continuing Medical Education (CME)

The 7th International Conference on Thrombosis and Hemostasis Issues in Cancer has been granted for CME accreditation by:

- **European Hematology Association (EHA)**
18 CME points

for European Hematologists

The program of the 7th ICTHIC has been reviewed and approved for CME accreditation by the European Hematology Association CME Unit.

The EHA-CME Unit has approved this educational activity for a maximum number of 18 CME credits.

Each physician should only claim credits for time that she/he actually spent in the educational activity.

- **European Society for Medical Oncology (ESMO)**

17 ESMO-MORA category 1 points

for European Medical Oncologists

- **Italy Ministry of Health (E.C.M.)**

for Italian delegates

22 credits for Medical Doctors (Hematology, Oncology, Transfusion Medicine, Clinical Biochemistry, Internal Medicine, Clinical Pathology), Biologists, Biomedical Laboratory Technicians and Nurses

The instructions and the forms for claiming CME Credits can be found in the Congress bag.

GENERAL INFORMATION



Badges

All the participants are kindly requested to wear the badge throughout the Conference. Only badge holders are admitted to the Scientific Sessions, Technical Exhibition, Welcome Reception, Coffee Breaks and Lunches. For the Social Events please bring with you the ticket(s) delivered at registration.

Name badges are colored as follows:

Faculty	Red
Delegate	Blue
Accompanying person	Green

Certificates of Attendance

The certificates will be delivered at the registration desk on Sunday May 11th starting from 13.00.

Posters

Mounting time

Posters have to be mounted in the **Poster Area** from 13.30 Friday May 9th and during meeting opening hours.

Viewing Time

In the Poster Area, from mounting to 11.00 Sunday May 11th.

Mandatory attendance

During the discussion (see below).

Discussion

There will be 6 Poster Sessions each guided by two co-chairs (duration = 1h15min), all held on Sunday May 11th in **Rooms A-B-C**. Sessions 1, 2, 3 will be held from 14.30 to 15.45; sessions 4, 5, 6 from 16.15 to 17.30. Posters will be moved from the Poster Area to the respective rooms for discussion by the congress organization at the end of viewing time.

Presenting authors are required to attend during the entire discussion session.

Some posters have been chosen by the session chairs to be briefly orally presented as a start for discussion: the authors are requested to present few Powerpoint slides in addition to the printed poster. These presentations must be uploaded directly in the room during or just before the start of the respective poster session: they have NOT to be submitted to the congress Slide Center.

Dismantling

From 17.30 to 18.00 Sunday May 11th. After this time all remaining posters will be destroyed by the organizing staff.

Dimensions

Maximum size of the Poster is **90 cm wide x 130 cm high** (vertical orientation). Material for poster mounting is available on site.

Slide Center

Slide center is located at the ground floor. All presenters should check in their slides or diskette/CD-ROM containing a PowerPoint presentation no later than 2 hours prior to the start of their session.

Language

The official language of the Conference is English. Translations are not provided.

Meals

Coffee/tea breaks and lunches are included in the Conference fee and are served in the catering areas located downstairs.

Technical exhibition

The technical exhibition is located in the foyer at the ground floor. The exhibition opening times are the same of the Conference.

Internet Point


It is located at the ground floor; close to the registration desk.



MEETING VENUE

Ground Floor

- 1** Slide Center
- 2** Registration Desk
- 3** Exhibition area
- 4** Auditorium
- 5** Internet point
- 6** Room B




MEETING VENUE



Basement

- 1** Room A
Catering area
Poster area
- 2** Room C
- 3** Catering area





SOCIAL PROGRAM

Social Events for Congress Delegates

Friday May 9th, 2014 - 20.30

Welcome reception

Included in the Registration Fee. This event will take place at Seminario Vescovile "Giovanni XXIII", Bergamo Alta (Upper Town).

Saturday May 10th, 2014

Presidential dinner

By invitation only (ticket needed).

Social Events for Accompanying Persons

Included in their registration fee

Friday May 9th, 2014 - 20.30

Visit to Bergamo Alta (Upper Town)

Meeting point: 15.45 at Seminario Vescovile "Giovanni XXIII", Via Arena, Bergamo Alta (Upper Town) with the tour guide.

From there you will start your pleasant tour of the medieval town in Piazza della Cittadella, built when Bergamo was under the control of the Visconti, Lords of Milan in the XIV century.

Then, you'll continue along Via Colleoni and Via Gombito, the main streets, lively and full of shops (open on Sundays too).

Then, you'll reach the magnificent Piazza Vecchia, one of the most beautiful squares in the world. It is the heart of the town, shaped by impressive monuments: the 12th century Town Hall and its civic bell tower (59 yards high), the Palladian style Library, and the Contarini fountain.

Just behind Piazza Vecchia, you will find another picturesque Landmark: Piazza Duomo with the Cathedral, Saint Mary's Church and the Shrine of Bartolomeo Colleoni.

Further on, at the end of the main street you'll find Piazza Mercato delle Scarpe and on your left a narrow street will take you to la Rocca (The Fort).

Friday May 9th, 2014 - 20.30

Welcome reception

Included in the Registration Fee. This event will take place at Seminario Vescovile "Giovanni XXIII", Bergamo Alta (Upper Town).

Saturday May 10th, 2014 8.00 - 18.00

Visit to Verona

Meeting Point: 8.00 at Seminario Vescovile "Giovanni XXIII", Via Arena, Bergamo Alta (Upper Town).

The bus will leave at 8.15.

The sightseeing consists in a walking tour in the old city-centre visiting the most characteristic points such as: Bra Square with the famous Roman Amphitheatre "Arena", Castle and Scaligero Bridge, Gavi Arch, Roman Gate "Porta Borsari", Juliet's House, Signori Square, Erbe Market Square, Scaligeri Tombs "Arche Scaligere", Romeo's House, and the Basilica of St. Anastasia.

Lunch in a restaurant in Verona.



SOCIAL PROGRAM



Sunday May 11th, 2014 10.00 – 11.30

Visit to Botanical Gardens of Bergamo "Lorenzo Rota"

Meeting point: 10.00 at Seminario Vescovile "Giovanni XXIII", Via Arena, Bergamo Alta (Upper Town).

If you happen to see a lotus flower, papyrus and a carnivorous *drosera carnifera* in the company of a Madagascar palm, the sanguisorba orobica, sugar cane and candelabra cactus you are probably at the Botanical Gardens of Bergamo.

foot: traffic, noise and anxiety must be left at the bottom of the Colle Aperto staircase, near the seventeenth century Powder Magazine. A beautiful panorama repays your efforts on arrival, the view sweeps across the rooftops and the monuments of the Città Alta to the foothills of the Prealps of Bergamo. The Botanical Gardens of Bergamo, with their demonstrative and suggestive character, help to bring the public closer to the world of plants and foster respect for nature. They carry out conservation activities for endangered plants and have undertaken projects for their reintroduction to their natural habitat. One of the latest successful ventures was the re-introduction of *Osmunda regalis*, a fern noted in 1853 by the botanist and doctor Lorenzo Rota, the first chronicler of the flora of Bergamo, who saw it in Val Calepio and on the banks of the River Adda. This fern, which had disappeared in the wild state for a few decades, was reintroduced about a dozen years ago. The Gardens exchange seeds, fruit and spores collected in the Gardens themselves or in the wild.



They are not the plant equivalent of the Tower of Babel, but rather a small feud of the Plant Kingdom which collects representatives of flora from the principle categories into which botanists subdivide the over 250,000 species on our planet.

Rich in plant life but not very big, the Botanical Gardens of Bergamo, which the magazine 'Gardenia' define as 'that hidden jewel', is set in the ring of the Mura Venete (Venetian Walls). The Gardens can be reached only on





CITY OF BERGAMO

The city of Bergamo is located in Northern Italy, 50 kilometers from Milan, in the borderland between the great plain of the Po Valley and the Alps.

Bergamo was founded on a hill by an ancient settlement in the prehistorical age, which gave it the configuration that still characterizes the oldest part of the town, enclosed within walls up on the hill, while the modern town has grown on the plain. Celts, Goths, Romans, Longbards resided on the hill, but little can now be seen of them; some of the most important monuments date back to the Middle Ages. The town reached its greatest splendor during the Renaissance when it became part of the Milan Signoria and then of the Venetian Republic. The four centuries under the Venetians were the most significant with respect to their cultural and historical impact on the city.



Città Alta (Upper Town), the old town situated on the hill and surrounded by sixteenth-century walls, has maintained the charm of its past over the centuries, with the magic and quiet atmosphere of its belfries, towers and squares. Città Bassa (Downtown), the modern town, has all the conveniences of a modern urban center. Thus, Bergamo is the town where old and new come together in a harmonious expression of life.

MAP OF BERGAMO



Meeting venue

- 1 Seminario Vescovile "Giovanni XXIII"

Hotels

- 2 Arli
- 3 Best Western Cappello d'Oro
- 4 Excelsior San Marco
- 5 Gombit
- 6 La Valleria Resort
- 7 Mercure Bergamo Palazzo Dolci
- 8 NH Bergamo Centro
- 9 Petronilla
- 10 Best Western Piemontese
- 11 Starhotel Cristallo Palace

to Strezzano



SCIENTIFIC SECRETARIAT

**Anna Falanga
Marina Marchetti
Alfonso Vignoli**

Department of Immunohematology
and Transfusion Medicine
Hospital Papa Giovanni XXIII
Piazza OMS, 1
24127 Bergamo - Italy
scientificsecretariat@icthic.com



ORGANIZING SECRETARIAT

Servizi C.E.C. Srl

Via G. Verdi, 18
24121 Bergamo - Italy
Phone +39.035.249899
Fax +39.035.237852
info@icthic.com